Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy-Reference-Cited by-同舟云学术

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy

Published:2006-10 Issue:10 Volume:28 Page:1485-1508
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Moreau Jacques-Pierre,Delavault Patrick,Blumberg Joëlle

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference136 articles.

1. EAU guidelines on prostate cancer;Aus;Eur Urol,2005

2. Prostate Cancer Treatment Guidelines for Patients-Version V;National Comprehensive Cancer Network in partnership with the American Cancer Society,2005

3. AstraZeneca Annual Report and Form 20-F Information 2004,2006

4. Commercial availability of QLT's Eligard® 6-month formulation brings new treatment option for advanced prostate cancer,2005

5. The use of gonadotrophinreleasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women;Robertson;Eur J Cancer,2003

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deer antlers: the fastest growing tissue with least cancer occurrence;Cell Death & Differentiation;2023-10-20

2. Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review;Frontiers in Endocrinology;2023-02-06

3. Translational aspect in peptide drug discovery and development: An emerging therapeutic candidate;BioFactors;2022-11-03

4. Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?;Cancers;2021-12-21

5. Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review;Translational Andrology and Urology;2021-10